OssiFi Therapeutics
Private Company
Total funding raised: $5.5M
Overview
OssiFi Therapeutics is a privately held, preclinical-stage biotech founded in 2019 and headquartered in the Boston area, with an operational office in Overland Park, KS. The company is developing best-in-class small molecule inhibitors of sclerostin to build bone, aiming for safer and more effective therapies than existing biologics. Its strategy combines therapeutic and device development to target neurogenic low back pain, fracture care, and osteoporosis, leveraging a management team with deep drug development expertise and a network of key clinical advisors in orthopedics and spine care.
Technology Platform
Small molecule inhibitors targeting the sclerostin pathway to promote bone anabolism, combined with medical device development for bone repair.
Funding History
1Opportunities
Risk Factors
Competitive Landscape
OssiFi competes in the bone anabolic space with Amgen/UCB's romosozumab (Evenity), an approved monoclonal antibody, and other companies developing biologic or alternative pathway modulators. Its small molecule approach differentiates it, but it faces competition from other biotechs pursuing similar strategies. In neurogenic pain and fracture repair devices, it will compete with various pharmacologic pain treatments, bone graft substitutes, and growth factor products.